ReviewFrontiers in genetics2022
Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy.
Review in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Sacituzumab govitecan as a therapeutic breakthrough in the treatment of triple-negative breast cancer: a systematic review of clinical trials.Frontiers in immunology · 2025Pooled it
- Current and future therapies for triple-negative breast cancer.Journal of hematology & oncology · 2026Review
- Genetic and Pharmacologic Targeting of Eya3 in Macrophages Drives Anti-Tumor Immunity in Triple-Negative Breast Cancer.bioRxiv : the preprint server for biology · 2026Article
- A pneumolysin mutant (ΔA146 ply) induces pyroptosis in triple-negative and HER2-positive breast cancer cells via the Caspase-1/GSDME pathway: a potential antibody-drug conjugate payload.Translational cancer research · 2026Article
- Single-cell profiling reveals a novel CAF subpopulation linking stromal heterogeneity to immune suppression in breast cancer subtypes.Journal of translational medicine · 2026Article
- Alterations in PD-L1Medicina (Kaunas, Lithuania) · 2026Article
- Prognostic relevance of specific TIL (CD4+, CD8+, and FOXP3 + T-cell infiltrates) in triple-negative breast cancer: short- and long-term outcomes.Breast cancer (Tokyo, Japan) · 2026Article
- Review
- Immunotherapy in triple-negative breast cancer: mechanisms of resistance and emerging approaches: a narrative review.Journal of Yeungnam medical science · 2026Article
- Huayu Wan enhances immune checkpoint inhibitor efficacy in triple-negative breast cancer by normalizing tumor vasculature and remodeling the tumor immune microenvironment.Frontiers in immunology · 2026Article
- Article
- Comparative Genomic and Microenvironmental Profiles of Hereditary and Sporadic TNBC in Colombian Women.Biology · 2025Article
- TMB as a predictive biomarker for ICI response in TNBC: current evidence and future directions for augmented anti-tumor responses.Clinical and experimental medicine · 2025Review
- The role of NETosis in breast cancer: mechanistic insights and biomarker potential.Breast cancer research : BCR · 2025Review
- Ferroptosis in TNBC: interplay with tumor-infiltrating immune cells and therapeutic implications.Molecular and cellular biochemistry · 2025Review
- Mapping molecular landscapes in triple-negative breast cancer: insights from spatial transcriptomics.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A Preliminary Study on the Therapeutic Role of γδT Cells in Triple-Negative Breast Cancer.The Kaohsiung journal of medical sciences · 2025Article
- Cancer Immunotherapy Based on the Bidirectional Reprogramming of the Tumor Microenvironment by a "Brakes Off/ Step on the Accelerator" Core-Shell Manganese Phosphate/siPD-L1 Modulator.Exploration (Beijing, China) · 2025Article
- Regulation of Different Types of Cell Death by Noncoding RNAs: Molecular Insights and Therapeutic Implications.ACS pharmacology & translational science · 2025Review
- Correlation study of tumor-infiltrating lymphocytes (TILs) and subtypes analysis before and after neoadjuvant chemotherapy in triple-negative breast cancer.Gland surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple negative breast cancer (TNBC) is a biologically diverse subtype of breast cancer characterized by genomic and transcriptional heterogeneity and exhibiting aggressive clinical behaviour and poor prognosis. In recent years, emphasis has been placed on the identification of mechanisms underlying the complex genomic and biological profile of TNBC, aiming to tailor treatment strategies. High immunogenicity, specific immune activation signatures, higher expression of immunosuppressive genes and higher levels of stromal Tumor Infiltrating Lymphocytes, constitute some of the key elements of the immune driven landscape associated with TNBC. The unprecedented response of TNBC to immunotherapy has undoubtedly changed the standard of care in this disease both in the early and the metastatic setting. However, the extent of interplay between immune infiltration and mutational signatures in TNBC is yet to be fully unravelled. In the present review, we present clinical evidence on the immunogenicity and tumour microenvironment influence on TNBC progression and the current treatment paradigms in TNBC based on immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.